Medicine
Carvykti 100000000 injectable suspension
Carvykti 100000000 injectable suspension is a prescription medicine containing Ciltacabtagene autoleucel for intravenous use, marketed by Janssen Biotech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store and transport below -120 °C, e.g., in a container for cryogenic storage…
Key facts
- Active ingredient (INN)
- Ciltacabtagene autoleucel
- Brand
- Carvykti
- Strength
- 100000000
- Dosage form
- Injectable suspension
- Route
- Intravenous
- Packs
- 1 injection
- Marketing authorisation holder
- Janssen Biotech
- Manufacturer
- Janssen Biotech
- Origin register
- US FDA, United States
- Storage
- Store and transport below -120 °C, e.g., in a container for cryogenic storage in the vapor phase of liquid nitrogen. Store CARVYKTI in the original packaging containing the cassette protecting the infusion bag.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XL05 Ciltacabtagene autoleucel
- HS code (indicative)
- 3002.51Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 February 2022
- Identifiers
- RxCUI 2594780, 2594786, 2594789 +1DailyMed set ID 7d040b91-3fb8-41db-ba7f-60a36f06e2c2NDC 57894-111Application BLA125746
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 injection, suspension in 1 bag | 57894-111-01 | Janssen Biotech | 28 February 2022 |
| 1 injection, suspension in 1 bag | 57894-111-02 | Janssen Biotech | 28 February 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ciltacabtagene autoleucel is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, among other approved uses. MedsAcross supplies Ciltacabtagene autoleucel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ciltacabtagene autoleucelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CARVYKTI prescribing information (Janssen Biotech) · U.S. National Library of Medicine, DailyMed
- Carvykti: European public assessment report (EPAR) · European Medicines Agency
Need Carvykti 100000000 injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.